focusIR Fireside Chats podcast - FTSE 250 Fund Manager Reveals Hidden Emerging Market Gems | Infrastructure. Watch here

Less Ads, More Data, More Tools Register for FREE

IN BRIEF: Craneware kicks off USD25 million buyback programme

Mon, 16th Mar 2026 13:25

Craneware PLC - Edinburgh-based software solutions provider - Commences the up to USD25 million buyback programme announced alongside its interim results earlier this month. Says it intends to hold any repurchased shares in treasury, "to cover existing share options and long-term incentive plan awards" for employees. Has engaged Peel Hunt LLP, Investec and Berenberg to conduct buybacks on its behalf. Adds that the programme will expire on the earlier of December 31, the conclusion of its next annual general meeting, or once the USD25 million total consideration limit has been reached.

"The board believes that the current market price does not reflect the large addressable market opportunity of the group or the strategic position the group has within US healthcare," Craneware says. "As a result, the board considers the share buyback programme, as part of its capital allocation strategy, to be an important component of shareholder returns, enhancing return on equity, increasing earnings per share and offsetting future dilution from existing employee share incentive schemes."

Current stock price: 1,435.00 pence, up 4.0% on Monday in London

12-month change: down 25%

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Corporate News Technology Craneware Peel Hunt Investec

Shares in this article

Related News

EARNINGS AND TRADING: Tekcapital swings to loss; Abingdon US update
5 hours ago

EARNINGS AND TRADING: Tekcapital swings to loss; Abingdon US update

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...

IN BRIEF: ValiRx subsidiary Cytolytix granted "core" European patent
6 hours ago

IN BRIEF: ValiRx subsidiary Cytolytix granted "core" European patent

ValiRx PLC - London-based life science company - Majority-owned subsidiary Cytolytix Ltd has its European patent "Nanoparticle for Anti-Cancer Peptide...

EARNINGS AND TRADING: GenIP revenue jumps to USD520,000 in 2025
6 hours ago

EARNINGS AND TRADING: GenIP revenue jumps to USD520,000 in 2025

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...

Corporate News Genip Plc + 6 more shares